Heartpoint Global Hopes To Disrupt Congenital Pulmonary Hypertension Treatment With Minimally Invasive Device

Heartpoint Global Hopes To Disrupt Congenital Pulmonary Hypertension Treatment With Minimally Invasive Device

To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one in five deaths in 2020 in theUnited States.
Even minimally invasive pulmonary artery banding — a surgical technique that has been in use since Harry Truman was president — requires access to the chest cavity. A new treatment under development by HeartPoint Global seeks to provide a minimally invasive alternative to current treatments for pulmonary arterial hypertension associated with Congenital Heart Disease.A device delivered through the leg would cost only…

Continue Reading